Previous 10 | Next 10 |
Image source: The Motley Fool. Accolade, Inc. (NASDAQ: ACCD) Q4 2022 Earnings Call Apr 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Accolade, Inc. (ACCD) Q4 2022 Earnings Call Transcript
Accolade, Inc. (ACCD) Q4 2022 Earnings Conference Call April 28, 2022, 04:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Medical Officer Conference Call Participants Michael Cherny - Bank of America Ryan Daniels - William Bla...
Accolade (NASDAQ:ACCD) stock sank 30% postmarket on Thursday after the healthcare firm reported Q4 results and provided disappointing outlook. Q4 GAAP EPS was -$0.51 vs. -$0.09 in Q4 2021 as operating expenses more than doubled Y/Y to ~$80M. Additionally, CEO Rajeev Singh said a large custome...
Accolade press release (NASDAQ:ACCD): Q4 GAAP EPS of -$0.51 misses by $0.12. Revenue of $93.76M (+58.4% Y/Y) beats by $2.18M. Shares -30.38%. For further details see: Accolade GAAP EPS of -$0.51 misses by $0.12, revenue of $93.76M beats by $2.18M
Fiscal fourth quarter 2022 revenue of $93.8 million, a 58% increase compared to fiscal fourth quarter 2021 revenue of $59.2 million Fiscal year 2022 revenue of $310.0 million, an 82% increase compared to fiscal year 2021 revenue of $170.4 million SEATTLE, April 28, 2022 (GLOBE N...
SEATTLE, April 14, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal fourth quarter and full year 2022 financial results on Thursday, April 28, 2022, after th...
Accolade (NASDAQ:ACCD) stock dropped to a 1-month low after Wells Fargo began coverage with an Underweight rating and price target of $9, implying 41.6% downside to its last close. In a note to clients, analyst Stan Berenshteyn said growth prospects for ACCD are attractive and it...
Guggenheim has initiated coverage of employee health benefits support provider Accolade with a neutral rating as the company will not be profitable until fiscal year 2025. The firm does not have a price target. Analyst Sandy Draper said that the company's offerings of personalized, data-drive...
Today, we put healthcare cloud concern Accolade in the spotlight for the first time. Despite solid growth and the addition of new capabilities since the company went public in July 2020, the stock finds itself in 'Busted IPO' territory. Brighter prospects for shareholders on the h...
Accolade Brings Proven Value to the Employee Experience Through Personalized Healthcare PR Newswire New third-party research demonstrates how Accolade enhances employee retention and recruitment, overall experience and satisfaction, and perception of health insuran...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 50.0% to $0.495 on volume of 360,218,139 shares NVIDIA Corporation (NVDA) fell 0.4% to $123.54 on volume of 307,578,749 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) rose 8.1% to $0.3343 on vol...